27 related articles for article (PubMed ID: 38493544)
1. Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling.
Chae YK; Chung SY; Davis AA; Carneiro BA; Chandra S; Kaplan J; Kalyan A; Giles FJ
Oncotarget; 2015 Nov; 6(35):37117-34. PubMed ID: 26359351
[TBL] [Abstract][Full Text] [Related]
2. Study of MYB-NFIB chimeric gene expression, tumor angiogenesis, and proliferation in adenoid cystic carcinoma of salivary gland.
Ono J; Okada Y
Odontology; 2018 Jul; 106(3):238-244. PubMed ID: 29243184
[TBL] [Abstract][Full Text] [Related]
3. The incidence of MYB gene breaks in adenoid cystic carcinoma of the salivary glands and its prognostic significance.
Broz M; Steiner P; Salzman R; Hauer L; Starek I
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Sep; 160(3):417-22. PubMed ID: 27174194
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of MYB promoter methylation in salivary adenoid cystic carcinoma.
Shao C; Bai W; Junn JC; Uemura M; Hennessey PT; Zaboli D; Sidransky D; Califano JA; Ha PK
Oral Oncol; 2011 Apr; 47(4):251-5. PubMed ID: 21324728
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic implications of Myb and Beta-catenin expression in adenoid cystic carcinoma.
Park S; Vora M; van Zante A; Humtsoe J; Kim HS; Yom S; Agarwal S; Ha P
J Otolaryngol Head Neck Surg; 2020 Jul; 49(1):48. PubMed ID: 32650834
[TBL] [Abstract][Full Text] [Related]
6. MYB alternative promoter activity is increased in adenoid cystic carcinoma metastases and is associated with a specific gene expression signature.
Huang J; Fehr A; Jäwert F; Nilsson JA; Morris LGT; Stenman G; Andersson MK
Oral Oncol; 2024 Apr; 151():106763. PubMed ID: 38493544
[TBL] [Abstract][Full Text] [Related]
7. The value of MYB as a prognostic marker for adenoid cystic carcinoma: Meta-analysis.
Liu X; Chen D; Lao X; Liang Y
Head Neck; 2019 May; 41(5):1517-1524. PubMed ID: 30759319
[TBL] [Abstract][Full Text] [Related]
8. MYB-NFIB fusion transcript in adenoid cystic carcinoma: Current state of knowledge and future directions.
Wagner VP; Bingle CD; Bingle L
Crit Rev Oncol Hematol; 2022 Aug; 176():103745. PubMed ID: 35738530
[TBL] [Abstract][Full Text] [Related]
9. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials.
Dillon PM; Chakraborty S; Moskaluk CA; Joshi PJ; Thomas CY
Head Neck; 2016 Apr; 38(4):620-7. PubMed ID: 25487882
[TBL] [Abstract][Full Text] [Related]
10. Adenoid cystic carcinoma: emerging role of translocations and gene fusions.
Wysocki PT; Izumchenko E; Meir J; Ha PK; Sidransky D; Brait M
Oncotarget; 2016 Oct; 7(40):66239-66254. PubMed ID: 27533466
[TBL] [Abstract][Full Text] [Related]
11. MYB-fusions and other potential actionable targets in adenoid cystic carcinoma.
Ferrarotto R; Heymach JV; Glisson BS
Curr Opin Oncol; 2016 May; 28(3):195-200. PubMed ID: 26974847
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
